keyword
MENU ▼
Read by QxMD icon Read
search

Review nhl treatment

keyword
https://www.readbyqxmd.com/read/27918211/new-targeted-therapies-for-malignant-lymphoma-based-on-molecular-heterogeneity
#1
Heike Horn, Annette M Staiger, German Ott
Owing to tremendous advances in the understanding of mechanisms involved in the pathogenesis of malignant tumors an emerging field of novel targeted drugs has evolved within the last decade. This is of particular interest also for malignant lymphomas, constituting a heterogeneous tumor category with substantial variation in clinical outcome, ranging from indolent forms that do not require treatment over years to aggressive cases for which an immediate treatment is mandatory. The elucidation of different molecular strategies adopted by malignant cells has led to a profound profiling of tumor-specific features and consequently resulted in the development of new targeted therapies...
December 5, 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27913533/non-hodgkin-lymphoma-across-the-pediatric-and-adolescent-and-young-adult-age-spectrum
#2
John T Sandlund, Mike G Martin
The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27906436/iliac-crest-bone-graft-a-23-years-hystory-of-infection-at-donor-site-in-vertebral-arthrodesis-and-a-review-of-current-bone-substitutes
#3
L Babbi, G Barbanti-Brodano, A Gasbarrini, S Boriani
OBJECTIVE: This is an exemplary case report underlining a relevant morbidity which could be associated to the use of autologous iliac crest bone graft (ICBG) for spine fusion. CASE REPORT: Starting from 1990, a 25-years-old woman underwent two subsequent surgical treatments for non-Hodgkin lymphoma vertebral localizations. In the second surgery, arthrodesis was obtained with autograft through right posterior iliac crest osteotomy. During the chemotherapy treatment following the surgery, the patient suffered from infection at posterior iliac crest scar, the site of previous graft, caused by methicillin-resistant Staphylococcus aureus...
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27900446/health-related-quality-of-life-and-symptoms-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-treated-in-the-phase-iii-gadolin-study-with-obinutuzumab-plus-bendamustine-versus-bendamustine-alone
#4
Bruce D Cheson, Peter C Trask, John G Gribben, Natalie Dimier, Eva Kimby, Pieternella J Lugtenburg, Catherine Thieblemont, Elisabeth Wassner-Fritsch, Aino Launonen, Laurie H Sehn
We present health-related quality of life (HRQoL) data from GADOLIN, comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered on day 1 of cycles 1, 3, and 5 during treatment, at end of induction (EOI), bi-monthly for 2 years during maintenance/follow-up, and annually during extended follow-up until progression/death. Time to first ≥6-point worsening from baseline in the FACT-Lym trial outcome index (TOI) was estimated...
November 30, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27895762/primary-renal-lymphoma-a-case-report-and-literature-review
#5
Xiaodong Chen, Danfei Hu, Laifu Fang, Yichen Chen, Xiaohang Che, Jin Tao, Guobin Weng, Xiaolei Ye
Primary renal lymphoma (PRL) is a rare disease, with no more than 70 cases reported in the literature. The present study reports the case of a 70-year-old woman with PRL. The patient was asymptomatic, however, a mass on the right kidney was identified incidentally during routine physical examination. Computed tomography revealed a mass in the right kidney that was 3.6 cm in diameter. Subsequently, right nephrectomy was performed. The histological evaluation of the nephrectomy specimen showed diffuse large B-cell non-Hodgkin's lymphoma...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27892666/mantle-cell-lymphoma-a-north-indian-tertiary-care-centre-experience
#6
Chandan Krushna Das, Ajay Gogia, Lalit Kumar, Atul Sharma, Mehar Chand Sharma, Saumya Ranjan Mallick
Background: Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin’s lymphoma, with a pathognomonic chromosomal translocation t (11;14). Prognosis is uniformly dismal but there is a paucity of information on MCL from India. Materials and methods: We retrospectively analysed clinicopathological information on all treated patients with MCL at our centre. STATA 14.0 was used for analysis. Survival was assessed by Kaplan-Meier analysis and the Cox’s proportional hazards method. Statistical significance was defined as a P value of < 0...
January 10, 2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27890995/endotracheobronchial-lymphoma-two-unusual-case-reports-and-review-of-article
#7
Trilok Chand, Avdhesh Bansal, Harsh Dua, Kapil Sharma
The tracheobronchial origin of non-Hodgkin's lymphoma (NHL) is a very rare presentation, and there are only a few case reports of primary tracheal or endobronchial NHL. We have two cases of primary tracheobronchial NHL; one case was incidentally diagnosed as anaplastic large cell lymphoma of endobronchial origin when a comprehensive workup and surgery were carried out for an endobronchial aspergilloma which was actually sitting on top of lymphoma. The second patient was a case of myelodysplastic syndrome who presented with acute respiratory distress; on thorough workup, he was found to have endotracheal B-cell lymphoma...
November 2016: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/27888878/the-spectrum-of-double-hit-lymphomas
#8
REVIEW
Jeremy S Abramson
Double-hit lymphomas (DHLs) characterize a unique subset of B-cell non-Hodgkin lymphomas. DHL typically presents in older adults with high-risk clinical features. This entity carries a significantly inferior prognosis compared with typical cases of diffuse large B-cell lymphoma; however, emerging literature can identify discrete clinical features within DHL that are associated with a favorable prognosis. Emerging literature is also demonstrating that intensive upfront treatment strategies may improve outcome...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27879369/standardized-response-assessment-criteria-and-their-applications-in-lymphoma-part-2
#9
Mateen Collis Moghbel, Erik Mittra, Andrea Gallamini, Ryan Niederkohr, Delphine Chen, Katherine Zukotynski, Helen Nadel, Lale Kostakoglu
Interim and end-of-treatment PET/CT have become central to the evaluation of Hodgkin's and non-Hodgkin's lymphoma. This review article seeks to aid clinical decision-making by providing an overview of available data on the diagnostic and prognostic value of PET/CT imaging for response assessment and pre-transplant evaluation in lymphoma. The relative strengths and limitations of these techniques in various disease subtypes and clinical scenarios are explored, along with their current standards for reporting and latest developments...
November 22, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27875673/recent-advances-in-engineered-t-cell-therapies-targeting-b-cell-malignancies
#10
Nathan Singh
Immunotherapy using engineered autologous T cells has been attempted for decades, but clinical trials have only recently demonstrated efficacy. The combination of enhanced manufacturing techniques, highly efficient engineering, appropriate target selection and synthetic receptors with potent T cell activating domains has led to the development of highly-active cellular therapy products. B-cell malignancies have served as the paradigmatic diseases to initially evaluate and subsequently hone engineered T cells targeting cancer...
October 2016: Discovery Medicine
https://www.readbyqxmd.com/read/27872741/novel-drugs-in-follicular-lymphoma
#11
REVIEW
Antonella Anastasia, Giuseppe Rossi
Follicular lymphoma(FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% of lymphoma diagnoses. The natural history of the disease is characterized by recurrent relapses and progressively shorter remissions with a median survival of 10yrs. The impossibility of achieving a definite cure, have prompted investigations into the possible role of more active and less toxic strategies with innovative therapeutic agents. Recently Casulo et al. demonstrated that approximately 20% of patients with FL relapse within two years after achieving remission with R-CHOP and have a poor prognosis...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27863759/outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-for-lymphomas-a-single-institution-experience
#12
Mira Romany Massoud, Paolo Fabrizio Caimi, Nicole Ferrari, Pingfu Fu, Richard Creger, Robert Fox, Joanne Carlson-Barko, Merle Kolk, Lauren Brister, Brenda Wimpfheimer Cooper, Stanton Gerson, Hillard Michael Lazarus, Marcos de Lima, Basem Magdy William
INTRODUCTION: Allogeneic hematopoietic stem cell transplantation offers the opportunity for extended survival in patients with Hodgkin's and non-Hodgkin lymphomas who relapsed after, or were deemed ineligible for, autologous transplantation. This study reports the cumulative experience of a single center over the past 14 years aiming to define the impact of patient, disease, and transplant-related characteristics on outcomes. METHODS: All patients with histologically confirmed diagnosis of Hodgkin's or non-Hodgkin lymphomas who received allogeneic transplantation from 2000 to 2014 were retrospectively studied...
October 2016: Revista Brasileira de Hematologia e Hemoterapia
https://www.readbyqxmd.com/read/27847267/primary-breast-lymphoma-analysis-of-55-cases-of-the-spanish-lymphoma-oncology-group
#13
Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José Miramón, Josep Gumá, Rut Álvarez, José Gómez-Codina, Francisco García Arroyo, Marta Llanos, Miguel Marin, Jesus Alfaro, Cristina Quero, Mayte Delgado, Esteban Nogales, Francisco Menarguez, Natividad Martinez, Maria Torrente, Ana Royuela, Delvys Abreu, Mariano Provencio
INTRODUCTION: Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. MATERIALS AND METHODS: We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated...
September 17, 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27823646/radioimmunotherapy-in-non-hodgkin-lymphoma-prediction-and-assessment-of-response
#14
REVIEW
Mahsa Eskian, MirHojjat Khorasanizadeh, Francoise Kraeber-Bodere, Nima Rezaei
Non-Hodgkin lymphoma (NHL) is one of the most common malignancies and a major cause of morbidity and mortality. Radioimmunotherapy (RIT) is a novel modality for treating NHL which offers the combined use of monoclonal antibodies for specific targeting of malignant cells and radiation for killing these cells. Despite the promising results favoring RIT in several clinical studies in different target populations and NHL types, Food and Drug Administration (FDA) approval for RIT agents is restricted to a limited number of indications and agents, maybe because of several ambiguities that still exist in the field...
November 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27811123/clinical-indications-impact-on-management-fourth-and-subsequent-post-therapy-follow-up-fdg-pet-ct-scans-in-oncology-patients
#15
Mehdi Taghipour, Charles Marcus, Sara Sheikhbahaei, Esther Mena, Shwetha Prasad, Abhinav K Jha, Lilja Solnes, Rathan M Subramaniam
INTRODUCTION: The Centers for Medicare and Medicaid Services (CMS) coverage includes three post-therapy FDG-PET/CT scans per patient and per tumor type. Any additional follow-up FDG-PET/CT will be reimbursed at the discretion of a local Medicare administrator, if deemed medically necessary. This study aims to investigate common clinical indications for performing a fourth or additional follow-up FDG-PET/CT scans which could impact management of patients. METHODS: This was a retrospective institutional review of 433 oncology patients (203 male, mean age 55 years), including a total of 1,659 fourth or subsequent follow-up PET/CT scans after completion of primary treatment...
November 3, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27807508/occurrence-of-lymphoma-in-non-gonadal-organ-during-pregnancy-a-report-on-four-cases-and-literature-review
#16
Da-Lin Gao, Qian-Qian Fu, Tian-Tian Zhang, Lin Sun, Yi Pan, Qiong-Li Zhai
Lymphoma rarely occurs during pregnancy, making this condition difficult to define. Lymphomas that occur in reproductive organs during pregnancy exhibit unique clinical characteristics. Among the limited cases, non-Hodgkin's lymphoma (NHL) shows a considerably higher incidence rate than Hodgkin's lymphoma (HL); NHL also displays clinical characteristics, such as high aggressiveness, advanced stage, and poor outcome. This study reports on four cases of lymphomas in non-gonadal organs (HL, n=2; NHL, n=2) during pregnancy...
September 2016: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/27807492/novel-brentuximab-vedotin-combination-therapies-show-promising-activity-in-highly-refractory-cd30-non-hodgkin-lymphoma-a-case-series-and-review-of-the-literature
#17
Wilfred Delacruz, Robert Setlik, Arash Hassantoufighi, Shyam Daya, Susannah Cooper, Dale Selby, Alexander Brown
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD)...
2016: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/27802434/outcome-comparison-of-allogeneic-versus-autologous-stem-cell-transplantation-in-transformed-low-grade-lymphoid-malignancies-a-systematic-review-and-pooled-analysis-of-comparative-studies
#18
Seongseok Yun, Nicole D Vincelette, Ivo Abraham, Soham Puvvada, Faiz Anwer
BACKGROUND: Some patients with low-grade lymphoid malignancies develop transformed disease, requiring stem cell transplantation (SCT). SCT outcomes in transformed low-grade lymphoid malignancies may differ from those of nontransformed disease or other aggressive non-Hodgkin lymphomas. We conducted a pooled analysis of the clinical outcomes of allogeneic versus high-dose therapy (HDT) with autologous SCT in adult patients with transformed low-grade lymphoid malignancies. METHODS: A PubMed, EMBASE, and Cochrane search yielded 4 comparative studies reporting allogeneic versus HDT with autologous SCT outcomes in adults (age ≥18) with transformed low-grade lymphoid malignancies, including follicular, chronic/small lymphocytic, and marginal zone lymphoma...
2016: Acta Haematologica
https://www.readbyqxmd.com/read/27793530/-primary-lymphoma-of-the-skull-case-report-and-literature-review
#19
K Issara, S Yossi, I Caraivan
Primitive lymphomas of the bone are exceptional tumors, representing 4% of all non-Hodgkin lymphomas. The location at the skull remains the rarest. We report the case of a 56 year old patient with lytic lesions in the skull of a small cell lymphoma B, treated with primary chemotherapy and intensity-modulated radiotherapy in arctherapy with a dose of 30Gy in 15 fractions. With a follow-up time of 18 months after the end of treatment, the patient has no sign of disease evolution.
December 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/27792043/the-role-of-18f-fdg-pet-and-pet-ct-in-the-evaluation-of-primary-cutaneous-lymphoma
#20
Lin Qiu, Guojian Tu, Jing Li, Yue Chen
Primary cutaneous lymphoma (PCL) is the second most common type of extranodal non-Hodgkin lymphoma, including both cutaneous T-cell and B-cell lymphomas. PCL comprises numerous subtypes and thus has myriad clinical presentations in the skin and subcutaneous tissues. Accurate classification and staging are important for making treatment recommendations for PCL and will further impact patient prognosis significantly. We review the role of fluorine-18-fluorodeoxyglucose (F-FDG) PET (F-FDG PET) and F-FDG PET with computed tomography (CT) in the diagnosis, staging, tumor biological evaluation, treatment response assessment, and early recurrence surveillance of PCL...
October 27, 2016: Nuclear Medicine Communications
keyword
keyword
19119
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"